ATE343388T1 - Pde-v hemmer zur behandlung von morbus parkinson - Google Patents
Pde-v hemmer zur behandlung von morbus parkinsonInfo
- Publication number
- ATE343388T1 ATE343388T1 AT01929063T AT01929063T ATE343388T1 AT E343388 T1 ATE343388 T1 AT E343388T1 AT 01929063 T AT01929063 T AT 01929063T AT 01929063 T AT01929063 T AT 01929063T AT E343388 T1 ATE343388 T1 AT E343388T1
- Authority
- AT
- Austria
- Prior art keywords
- disease
- parkinson
- pde
- inhibitor
- treatment
- Prior art date
Links
- 208000018737 Parkinson disease Diseases 0.000 title abstract 2
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 title 1
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 abstract 1
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- ZOOGRGPOEVQQDX-UHFFFAOYSA-N cyclic GMP Natural products O1C2COP(O)(=O)OC2C(O)C1N1C=NC2=C1NC(N)=NC2=O ZOOGRGPOEVQQDX-UHFFFAOYSA-N 0.000 abstract 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19818000P | 2000-04-19 | 2000-04-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE343388T1 true ATE343388T1 (de) | 2006-11-15 |
Family
ID=22732318
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01929063T ATE343388T1 (de) | 2000-04-19 | 2001-04-17 | Pde-v hemmer zur behandlung von morbus parkinson |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20020006926A1 (de) |
| EP (1) | EP1278522B1 (de) |
| JP (1) | JP2004500425A (de) |
| CN (1) | CN1436080A (de) |
| AT (1) | ATE343388T1 (de) |
| AU (2) | AU5584901A (de) |
| CA (1) | CA2407031A1 (de) |
| DE (1) | DE60124085D1 (de) |
| WO (1) | WO2001078711A2 (de) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10135815A1 (de) * | 2001-07-23 | 2003-02-06 | Bayer Ag | Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen |
| EP1575916B1 (de) | 2001-08-31 | 2013-05-22 | The Rockefeller University | Phosphodiesteraseaktivität und regulation der durch phosphodiesterase-1-b vermittelten signalvermittlung im hirn |
| US8338420B1 (en) | 2002-12-04 | 2012-12-25 | Mitsubishi Tanabe Pharma Corporation | Treatment of Parkinson's disease and enhancement of dopamine signal using PDE 10 inhibitor |
| US20050048573A1 (en) * | 2003-02-03 | 2005-03-03 | Plexxikon, Inc. | PDE5A crystal structure and uses |
| WO2006133261A2 (en) | 2005-06-06 | 2006-12-14 | Intra-Cellular Therapies, Inc. | Organic compounds |
| EP1919287A4 (de) * | 2005-08-23 | 2010-04-28 | Intra Cellular Therapies Inc | Organische verbindungen zur behandlung einer verringerten dopamin-rezeptorsignalisierungs-aktivität |
| US8809310B2 (en) | 2006-02-21 | 2014-08-19 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline for the treatment of multiple system atrophy |
| AU2007256633B2 (en) * | 2006-06-06 | 2013-09-12 | Intra-Cellular Therapies, Inc. | Organic compounds |
| TW200815045A (en) * | 2006-06-29 | 2008-04-01 | Jazz Pharmaceuticals Inc | Pharmaceutical compositions of ropinirole and methods of use thereof |
| US8841300B2 (en) | 2006-10-02 | 2014-09-23 | Jerry M. Held | Treatment for Parkinson's disease—combination high dose serotonergic synaptic reuptake inhibitor with phosphodiesterase inhibitor |
| WO2008063505A1 (en) * | 2006-11-13 | 2008-05-29 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2008070095A1 (en) | 2006-12-05 | 2008-06-12 | Intra-Cellular Therapies, Inc. | Novel uses |
| CN101754756A (zh) * | 2007-05-18 | 2010-06-23 | 维瓦斯公司 | 包含磷酸二酯酶-5抑制剂的新组合和它们的用途 |
| EP2939676A1 (de) * | 2007-12-06 | 2015-11-04 | Intra-Cellular Therapies, Inc. | Organische Verbindungen |
| ES2588238T3 (es) * | 2007-12-06 | 2016-10-31 | Intra-Cellular Therapies, Inc. | Derivados de pirazolopirimidin-4,6-diona y su uso como producto farmacéutico |
| RU2540470C9 (ru) | 2008-06-06 | 2015-07-20 | Фарма Ту Б Лтд. | Фармацевтические композиции для лечения болезни паркинсона |
| AU2009322903A1 (en) | 2008-12-06 | 2010-06-10 | Intra-Cellular Therapies, Inc. | Organic compounds |
| MX2011005934A (es) | 2008-12-06 | 2011-12-16 | Intra Cellular Therapies Inc | Compuestos organicos. |
| AU2009322899A1 (en) | 2008-12-06 | 2010-06-10 | Intra-Cellular Therapies, Inc. | Organic compounds |
| EA201170769A1 (ru) * | 2008-12-06 | 2012-02-28 | Интра-Селлулар Терапиз, Инк. | Органические соединения |
| BRPI0922700A2 (pt) | 2008-12-06 | 2015-08-11 | Intracellular Therapies Inc | Compostos orgânicos |
| PE20110922A1 (es) | 2008-12-06 | 2012-01-22 | Intra Cellular Therapies Inc | DERIVADOS DE PIRAZOLO[4,3-e]PIRIMIDIN COMO INHIBIDORES DE LA FOSFODIESTERASA 1 (PDE1) |
| WO2010098839A1 (en) | 2009-02-25 | 2010-09-02 | Intra-Cellular Therapies, Inc. | Pde 1 inhibitors for ophthalmic disorders |
| EP2434895A4 (de) | 2009-05-13 | 2013-08-07 | Intra Cellular Therapies Inc | Organische verbindungen |
| WO2011016861A2 (en) | 2009-08-05 | 2011-02-10 | Intra-Cellular Therapies, Inc. | Novel regulatory proteins and inhibitors |
| US9371327B2 (en) | 2010-05-31 | 2016-06-21 | Intra-Cellular Therapies, Inc. | PDE1 inhibitor compounds |
| EP2575817A4 (de) | 2010-05-31 | 2014-01-08 | Intra Cellular Therapies Inc | Organische verbindungen |
| TW201206937A (en) | 2010-05-31 | 2012-02-16 | Intra Cellular Therapies Inc | Organic compounds |
| US9763948B2 (en) | 2010-05-31 | 2017-09-19 | Intra-Cellular Therapies, Inc. | PDE1 inhibitory compounds and methods |
| EP2717877B1 (de) * | 2011-06-10 | 2017-11-08 | Intra-Cellular Therapies, Inc. | Organische verbindungen |
| US20150086481A1 (en) * | 2011-07-28 | 2015-03-26 | Memorial Sloan-Kettering Cancer Center | Diagnosis and treatment of parkinson's disease |
| EP2956141A4 (de) | 2013-02-17 | 2016-10-26 | Intra Cellular Therapies Inc | Neuartige verwendungen |
| DK2970279T3 (da) | 2013-03-15 | 2020-11-30 | Intra Cellular Therapies Inc | Organiske forbindelser |
| ES2717688T3 (es) | 2013-03-15 | 2019-06-24 | Intra Cellular Therapies Inc | Inhibidores de la PDE1 para uso en el tratamiento y/o prevención de lesiones de SNC, y enfermedades, trastornos o lesiones de SNP |
| US9463186B2 (en) | 2013-04-15 | 2016-10-11 | Northwestern University | Treatment for dopaminergic disorders |
| JP6696904B2 (ja) | 2014-01-08 | 2020-05-20 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 製剤および医薬組成物 |
| DK3157926T3 (da) | 2014-06-20 | 2019-08-19 | Intra Cellular Therapies Inc | Organiske forbindelser |
| US9546175B2 (en) | 2014-08-07 | 2017-01-17 | Intra-Cellular Therapies, Inc. | Organic compounds |
| US10285992B2 (en) | 2014-08-07 | 2019-05-14 | Intra-Cellular Therapies, Inc. | Combinations of PDE1 inhibitors and NEP inhibitors and associated methods |
| US10131671B2 (en) | 2014-08-07 | 2018-11-20 | Intra-Cellular Therapies, Inc. | Organic compounds |
| CA2961212C (en) | 2014-09-17 | 2024-02-06 | Intra-Cellular Therapies, Inc. | Compounds and methods |
| BR112017012007B1 (pt) | 2014-12-06 | 2022-11-01 | Intra-Cellular Therapies, Inc | Compostos orgânicos inibitórios de pde2, composições farmacêuticas compreendendo os ditos compostos e uso dos mesmos no tratamento de um distúrbio mediado por pde2 |
| WO2016090382A1 (en) | 2014-12-06 | 2016-06-09 | Intra-Cellular Therapies, Inc. | Organic compounds |
| US10682354B2 (en) | 2016-03-28 | 2020-06-16 | Intra-Cellular Therapies, Inc. | Compositions and methods |
| WO2017168174A1 (en) | 2016-04-02 | 2017-10-05 | N4 Pharma Uk Limited | New pharmaceutical forms of sildenafil |
| US11291666B2 (en) | 2016-09-12 | 2022-04-05 | Intra-Cellular Therapies, Inc. | Uses |
| MA47685A (fr) * | 2017-03-02 | 2020-01-08 | Univ Amsterdam | Augmentation spécifique de la synthèse de la dopamine par ciblage du récepteur de la guanylate cyclase 2c dans le traitement de la maladie de parkinson |
| JP7401442B2 (ja) | 2018-01-31 | 2023-12-19 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 新規使用 |
| JP2021535180A (ja) * | 2018-09-05 | 2021-12-16 | ユニベルシテイト ファン アムステルダム | パーキンソン病の処置の為のｐｄｅ１１又はｐｄｅ２阻害剤の使用 |
| US12410175B2 (en) | 2019-09-03 | 2025-09-09 | Intra-Cellular Therapies, Inc. | Compounds |
| US12364695B2 (en) | 2020-06-02 | 2025-07-22 | Intra-Cellular Therapies, Inc. | Methods of treating inflammatory disease |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4147789A (en) * | 1974-03-14 | 1979-04-03 | Sandoz Ltd. | 6-Methyl-8-thiomethyl-ergolene derivatives |
| DE69426804D1 (de) | 1993-05-27 | 2001-04-12 | Icos Corp | Cyclisch gmp bindende cyclisch gmp spezifische phosphodiesterase materialien und verfahren. |
| GB9514465D0 (en) | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Chemical compounds |
| GB9401090D0 (en) | 1994-01-21 | 1994-03-16 | Glaxo Lab Sa | Chemical compounds |
| GB9514473D0 (en) | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Chemical compounds |
| EP0882718B1 (de) * | 1995-12-28 | 2005-08-31 | Fujisawa Pharmaceutical Co., Ltd. | Benzimidazolderivate |
| ATE215950T1 (de) | 1996-05-10 | 2002-04-15 | Icos Corp | Carbolinderivate |
| IL132993A0 (en) | 1997-05-29 | 2001-03-19 | Mochida Pharm Co Ltd | Therapeutic agent for erection failure |
| WO1999021831A1 (en) | 1997-10-27 | 1999-05-06 | Fujisawa Pharmaceutical Co., Ltd. | Tricyclic compounds as cgmp-pde inhibitors |
| HU227841B1 (en) | 1997-11-12 | 2012-05-02 | Bayer Pharma AG | 2-phenyl substituted imidazotriazinones, process for their preparation and pharmaceutical compositions thereof |
| AU5067098A (en) | 1997-11-26 | 1999-06-15 | Mochida Pharmaceutical Co., Ltd. | Pyridocarbazole derivatives with cgmp-pde inhibitory activity |
| ZA9810766B (en) | 1997-11-28 | 1999-05-25 | Mochida Pharm Co Ltd | Novel compounds having cgmp-pde inhibitory activity |
| DE19752952A1 (de) | 1997-11-28 | 1999-06-02 | Merck Patent Gmbh | Thienopyrimidine |
| CA2314339C (en) * | 1997-12-12 | 2009-09-08 | Cell Pathways, Inc. | N-benzyl-3-indenylacetamide derivatives for treating neoplasia |
| RU2229476C2 (ru) | 1998-02-19 | 2004-05-27 | Эйсай Ко., Лтд. | Производные фталазина и терапевтические средства для эректильной дисфункции |
| DE69906059D1 (de) | 1998-04-20 | 2003-04-24 | Fujisawa Pharmaceutical Co | Anthranilsäurederivate als inhibitoren der c-gmp-phosphodiesterase |
| ES2203078T3 (es) * | 1998-04-20 | 2004-04-01 | Pfizer Inc. | Parazolopirimidinonas inhibidoras de gmpc pde5 para el tratamiento de la disfuncion sexual. |
| AU775102B2 (en) * | 1999-09-13 | 2004-07-15 | David M. Swope | Composition and method for decreasing neurologic symptomatology |
-
2001
- 2001-04-17 CN CN01811222A patent/CN1436080A/zh active Pending
- 2001-04-17 EP EP01929063A patent/EP1278522B1/de not_active Expired - Lifetime
- 2001-04-17 US US09/836,744 patent/US20020006926A1/en not_active Abandoned
- 2001-04-17 AT AT01929063T patent/ATE343388T1/de not_active IP Right Cessation
- 2001-04-17 JP JP2001576012A patent/JP2004500425A/ja not_active Withdrawn
- 2001-04-17 DE DE60124085T patent/DE60124085D1/de not_active Expired - Lifetime
- 2001-04-17 AU AU5584901A patent/AU5584901A/xx active Pending
- 2001-04-17 WO PCT/US2001/040538 patent/WO2001078711A2/en not_active Ceased
- 2001-04-17 AU AU2001255849A patent/AU2001255849B8/en not_active Ceased
- 2001-04-17 CA CA002407031A patent/CA2407031A1/en not_active Abandoned
- 2001-11-21 US US09/989,672 patent/US6492371B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2407031A1 (en) | 2001-10-25 |
| US20020077274A1 (en) | 2002-06-20 |
| US6492371B2 (en) | 2002-12-10 |
| WO2001078711A2 (en) | 2001-10-25 |
| AU2001255849B8 (en) | 2006-04-27 |
| CN1436080A (zh) | 2003-08-13 |
| AU5584901A (en) | 2001-10-30 |
| US20020006926A1 (en) | 2002-01-17 |
| EP1278522A2 (de) | 2003-01-29 |
| AU2001255849B2 (en) | 2005-12-22 |
| JP2004500425A (ja) | 2004-01-08 |
| EP1278522B1 (de) | 2006-10-25 |
| DE60124085D1 (de) | 2006-12-07 |
| WO2001078711A3 (en) | 2002-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60124085D1 (de) | Pde-v hemmer zur behandlung von morbus parkinson | |
| ATE389395T1 (de) | Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson | |
| EA200201247A1 (ru) | Соединения для лечения болезни альцгеймера | |
| DE60124080D1 (de) | Verbindungen und verfahren zur behandlung der alzheimerschen krankheit | |
| DE60112942D1 (de) | Verbindungen zur behandlung der alzheimerischen krankheit | |
| ATE355374T1 (de) | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen | |
| EA200600294A1 (ru) | [1,8] нафтиридин-2-оны и родственные соединения для лечения шизофрении | |
| GB0318447D0 (en) | Therapeutic agents | |
| EA200300528A1 (ru) | 1-арил-или 1-алкилсульфонилгетероциклилбензазолы в качестве лигандов 5-гидрокситриптамина-6 | |
| WO2002002520A3 (en) | Compounds to treat alzheimer's disease | |
| ATE254461T1 (de) | Behandlung von augenschmerzen | |
| EA200200716A1 (ru) | Арилконденсированные азаполициклические соединения | |
| EA200401114A2 (ru) | Замещённые гидроксиэтиламины | |
| EA200601212A1 (ru) | Ингибиторы фосфодиэстеразы, получение и их терапевтическое применение | |
| IL162515A0 (en) | Substituted diketopiperazines as oxytocin antagonists | |
| DE60142037D1 (de) | Nasale verabreichung von metoclopramid zur behandlung der gastroparese | |
| ATE464048T1 (de) | Behandlung von alzheimer-krankheit und verwandten zuständen | |
| ATE437855T1 (de) | (4,5,6,7-tetrahydro-1h-indol-7- yl)essigsäurederivate zur behandlung von alzheimer-krankheit | |
| ATE315387T1 (de) | Verwendung von substituierten 6- dimethylaminomethyl-1-phenyl- cyclohexanverbindungen zur therapie der harninkontinenz | |
| DE60330233D1 (de) | Arsentherapie zur behandlung von autoimmunerkrankungen | |
| DE59609219D1 (de) | Verwendung von 1-hydroxy-2-pyridonen zur behandlung von schwer therapierbaren schleimhauterkrankungen | |
| DE60108775T8 (de) | Methode zur behandlung von schlaganfall | |
| DE60310975D1 (de) | Verwendung von epothilone zur behandlung hyperparathyreoidismus | |
| ATE431348T1 (de) | Thiaepothilone zur behandlung von krebserkrankungen | |
| EA201001895A1 (ru) | Пролекарства возбуждающих аминокислот |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |